Remifentanil HCl active pharmaceutical ingredient (API) for manufacturing, processing or repackag...

FDA Drug Recall #D-1252-2019 — Class III — April 2, 2019

Recall Summary

Recall Number D-1252-2019
Classification Class III — Low risk
Date Initiated April 2, 2019
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Johnson Matthey Inc.
Location West Deptford, NJ
Product Type Drugs
Quantity 416.95 g glass container

Product Description

Remifentanil HCl active pharmaceutical ingredient (API) for manufacturing, processing or repackaging, 416.95 g glass container, Rx ONLY, Johnson Matthey Pharmaceutical Materials, 2003 Nolte Drive, West Deptford, NJ 08066-1742.

Reason for Recall

Failed Impurities/Degradation Specifications: Unknown impurity above specification limits.

Distribution Pattern

Product was distributed to one manufacturer in Morgantown, WV who may have manufactured the product into finished product and further distribute to the retail level Nationwide in the USA.

Lot / Code Information

Lot #: B1319-170101

Other Recalls from Johnson Matthey Inc.

Recall # Classification Product Date
D-1880-2019 Class II Fentanyl Citrate Active Pharmaceutical Ingredie... Aug 29, 2019
D-1881-2019 Class II Cisplatin Active Pharmaceutical Ingredient, Joh... Aug 29, 2019
D-1882-2019 Class II Oxaliplatin Active Pharmaceutical Ingredient, J... Aug 29, 2019
D-1077-2019 Class II Morphine Sulfate USP Milled, Active Pharmaceuti... Mar 5, 2018

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.